Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24 -deficient mice

Jie Zhang,Pengfei Sun,Zhuping Wu,Jie Wu,Jiali Jia,Haoman Zou,Yanzhen Mo,Zhongjun Zhou,Baohua Liu,Ying Ao,Zimei Wang

DOI: https://doi.org/10.1038/s41419-024-06760-0

2024-05-31

Cell Death and Disease

Abstract:Senescent cell clearance is emerging as a promising strategy for treating age-related diseases. Senolytics are small molecules that promote the clearance of senescent cells; however, senolytics are uncommon and their underlying mechanisms remain largely unknown. Here, we investigated whether genomic instability is a potential target for senolytic. We screened small-molecule kinase inhibitors involved in the DNA damage response (DDR) in Zmpste24 −/− mouse embryonic fibroblasts, a progeroid model characterized with impaired DDR and DNA repair. 4,5,6,7-tetrabromo-2-azabenzamidazole (TBB), which specifically inhibits casein kinase 2 (CK2), was selected and discovered to preferentially trigger apoptosis in Zmpste24 −/− cells. Mechanistically, inhibition of CK2 abolished the phosphorylation of heterochromatin protein 1α (HP1α), which retarded the dynamic HP1α dissociation from repressive histone mark H3K9me3 and its relocalization with γH2AX to DNA damage sites, suggesting that disrupting heterochromatin remodeling in the initiation of DDR accelerates apoptosis in senescent cells. Furthermore, feeding Zmpste24 -deficient mice with TBB alleviated progeroid features and extended their lifespan. Our study identified TBB as a new class senolytic compound that can reduce age-related symptoms and prolong lifespan in progeroid mice.

cell biology

What problem does this paper attempt to address?

The aim of this paper is to find a new method to clear senescent cells, thereby delaying age-related diseases and extending lifespan. Specifically, the researchers screened kinase inhibitors related to the DNA damage response (DDR) in Zmpste24−/− mouse embryonic fibroblasts (MEFs) to identify small molecule compounds that can selectively induce apoptosis in senescent cells. Through screening, it was found that 4,5,6,7-tetrabromo-2-azabenzamide (TBB), as an inhibitor of casein kinase 2 (CK2), can effectively clear senescent cells with DDR defects and alleviate the progeroid phenotype in the Zmpste24−/− mouse model, thereby extending their lifespan. Mechanistically, CK2 promotes the dynamic dissociation of heterochromatin protein HP1α from histone mark H3K9me3 and its relocation to DNA damage sites through phosphorylation, while TBB inhibits CK2, leading to exacerbated DDR dysfunction and ultimately triggering apoptosis in senescent cells. Therefore, this study reveals the potential of TBB as a novel senolytic drug and its potential application value in treating progeroid syndromes such as Hutchinson-Gilford Progeria Syndrome (HGPS).